PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors

Phase 3

Recruiting

Conditions: Hemophilia A
Hemophilia B

Interventions: Drug: PF-06741086

First Posted Date: 2021-12-06

Last Posted Date: 2024-12-24

Lead Sponsor: Pfizer

Target Recruit Count: 245

Registration Number: NCT05145127

Locations: 🇺🇸
University of Iowa, Iowa City, Iowa, United States
🇺🇸
Northwell Health HTC, New Hyde Park, New York, United States
🇺🇸
Washington Institute for Coagulation d/b/a WACBD, Seattle, Washington, United States

and more 49 locations

Treatment Patterns and Clinical Outcomes Among Talazoparib-Treated Adults With HER2-Negative mBC With gBRCA1/2m

Completed

Conditions: Metastatic Breast Cancer
Breast Neoplasms

Interventions: Drug: Talazoparib

First Posted Date: 2021-12-02

Last Posted Date: 2024-02-16

Lead Sponsor: Pfizer

Target Recruit Count: 33

Registration Number: NCT05141708

Locations: 🇺🇸
Pfizer Inc., New York, New York, United States

A Study to Assess the Hemodynamic Effects, Safety, Tolerability, and Pharmacokinetics of Intravenous APD418 in Adult Participants With Heart Failure With Reduced Ejection Fraction

Phase 2

Terminated

Conditions: Acute Heart Failure With Reduced Ejection Fraction

Interventions: Drug: APD418
Drug: Placebo

First Posted Date: 2021-12-01

Last Posted Date: 2023-11-09

Lead Sponsor: Pfizer

Target Recruit Count: 22

Registration Number: NCT05139615

Locations: 🇷🇸
Institute for Cardiovascular Diseases of Vojvodina, Sremska Kamenica, Serbia
🇷🇸
Clinical Center of Kragujevac, Kragujevac, Serbia
🇷🇸
Healthcare Center Uzice, Užice, Serbia

and more 18 locations

This Study Will Examine the Clinical Effectiveness of Tafamidis in Patients With Mixed Phenotype Hereditary Transthyretin Amyloidosis

Completed

Conditions: Hereditary Transthyretin Amyloidosis (ATTRv) Cardiomyopathy (CM), Mixed Phenotype

Interventions: Drug: tafamidis

First Posted Date: 2021-12-01

Last Posted Date: 2023-08-09

Lead Sponsor: Pfizer

Target Recruit Count: 10

Registration Number: NCT05139680

Locations: 🇺🇸
Pfizer, New York, New York, United States

Analysis of the Real-world Prescription Pattern of Palbociclib Combination Therapy With Aromatase Inhibitor as a First Line Therapy in Metastatic Breast Cancer Patients Using the National Health Insurance Claims Data in South Korea

Active, not recruiting

Conditions: Metastatic Breast Cancer

First Posted Date: 2021-11-24

Last Posted Date: 2023-04-10

Lead Sponsor: Pfizer

Target Recruit Count: 1

Registration Number: NCT05132101

Locations: 🇰🇷
Pfizer Local Country Office, Seoul, Korea, Republic of

Korean Regulatory Post Marketing Surveillance for Somavert

Recruiting

Conditions: Acromegaly

Interventions: Drug: Somavert

First Posted Date: 2021-11-23

Last Posted Date: 2024-11-01

Lead Sponsor: Pfizer

Target Recruit Count: 100

Registration Number: NCT05131100

Locations: 🇰🇷
Pfizer, Seoul, Korea, Republic of

Food Effect Study to Evaluate the Effect of High-Fat Meal on the Relative Bioavailability of PF-07321332 Boosted With Ritonavir in Healthy Adult Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: PF-07321332/ritonavir
Drug: Ritonavir

First Posted Date: 2021-11-22

Last Posted Date: 2023-10-05

Lead Sponsor: Pfizer

Target Recruit Count: 12

Registration Number: NCT05129475

Locations: 🇺🇸
New Haven Clinical Research Unit, New Haven, Connecticut, United States

A Target Occupancy Study With Ritlecitinib.

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Ritlecitinib 50 mg
Drug: Ritlecitinib 200 mg

First Posted Date: 2021-11-19

Last Posted Date: 2023-11-13

Lead Sponsor: Pfizer

Target Recruit Count: 16

Registration Number: NCT05128058

Locations: 🇺🇸
Pfizer Clinical Research Unit - New Haven, New Haven, Connecticut, United States

Continuation Study of Long-term Safety, Tolerability, Pharmacokinetics and Efficacy of Recifercept in Achondroplasia

Phase 2

Terminated

Conditions: Achondroplasia

Interventions: Biological: Recifercept

First Posted Date: 2021-11-10

Last Posted Date: 2024-02-08

Lead Sponsor: Pfizer

Target Recruit Count: 35

Registration Number: NCT05116046

Locations: 🇺🇸
Long Beach Memorial Medical Center, Long Beach, California, United States
🇺🇸
Nemours Children's Hospital, Delaware, Wilmington, Delaware, United States
🇦🇺
Murdoch Children's Research Institute, Parkville, Victoria, Australia

and more 10 locations

Assessment of the Effectiveness and Safety Outcome in Patients With Atrial Fibrillation Treated by Apixaban in Belgium

Withdrawn

Conditions: Atrial Fibrillation

First Posted Date: 2021-11-10

Last Posted Date: 2023-05-17

Lead Sponsor: Pfizer

Registration Number: NCT05116267

Locations: 🇧🇪
Pfizer Site, Brussels, Belgium

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy